Evidence map›Paper›PMID 34709970›Full record

ArticleBioengineered2021

Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis.

Linyong Wu, Wei Liao, Xiaodong Wang, Yujia Zhao, Jinshu Pang, Yuji Chen, Hong Yang, Yun He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Linyong WuDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Wei LiaoDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Xiaodong WangDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Yujia ZhaoDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Jinshu PangDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Yuji ChenDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Hong YangDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Yun HeDepartment of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
First Affiliated Hospital of GuangXi Medical University · CNGuangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNA known as ASB16 antisense RNA1 (ASB16-AS1) has been proven to be an oncogene, and the relationship between ASB16-AS1 and immunity is still under studied. This study aims to explore the expression and prognostic potential of ASB16-AS1, and to visualize the relationship between ASB16-AS1 expression and immune infiltration in pan-cancer analysis. We clarified ASB16-AS1 expression patterns and its relationship with prognosis through multi-platform and multi-database sources. We also verified the function of ASB16-AS1 in liver hepatocellular carcinoma (LIHC). A  variety of immune cell content evaluation methods were used to mutually verify the correlation between ASB16-AS1 and immune infiltration. Finally, the relationships between ASB16-AS1 and molecular characteristics were further explored. In terms of comprehensive analysis, compared with non-tumor tissues, ASB16-AS1 was highly expressed in tumor tissues, and indicated the value of poor prognosis in multiple cancer types. Functional assays, such as counting kit-8 assay, transwell assay and scratch-wound assay verified that high ASB16-AS1 expression promoted tumor progression in LIHC. ASB16-AS1 was positively correlated with B cells, T cells CD4+ and T cells CD8+ in most cancer types, and negatively correlated with macrophages, dendritic cells and neutrophils in some cancer types. In addition, there were different interaction modes between ASB16-AS1 and molecular features, such as the relationship with oncogenic signaling pathways, showing that the high ASB16-AS1 expression was related to alterations in oncogenic signaling pathways. Our study emphasizes that ASB16-AS1 is a potential pan-cancer prognostic marker, whichs is associated with the immune infiltration in multiple cancer types.

Indexed as

Gene Expression Regulation, NeoplasticCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationHumansLiver NeoplasmsMultivariate AnalysisNeoplasm InvasivenessNeoplasmsPrognosisProportional Hazards ModelsReproducibility of ResultsRNA, Long NoncodingTranscriptomeUp-RegulationRNA, Long NoncodingImmune infiltrationLong non-coding RNA ASB16-AS1Molecular characteristicsPan-cancerPrognosis

Identifiers

PMID34709970
PMCPMC8810074
OpenAlexW3211040279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.